PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33570057-5	2021	Rhamnetin treatment decreased expression of the drug resistance-related downstream genes of PXR (cyp3a4 [cytochrome P-450] or mdr-1 [multi-drug resistance 1]), which mediate the metabolism or elimination of sorafenib in HCC cells.	Sorafenib	207-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-121	
22927483-3	2012	Sorafenib metabolism was evaluated in vitro at 10 mumol/L using a panel of purified human cytochrome P450 (CYP) enzymes.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	90-105	
22927483-3	2012	Sorafenib metabolism was evaluated in vitro at 10 mumol/L using a panel of purified human cytochrome P450 (CYP) enzymes.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-110	
21350850-1	2011	BACKGROUND: In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.	Sorafenib	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-96	
21350850-1	2011	BACKGROUND: In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6.	Sorafenib	44-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101	
24797816-1	2014	BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation.	Sorafenib	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-130	
24797816-1	2014	BACKGROUND: Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation.	Sorafenib	12-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-135	
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-40	
22513143-2	2012	Sorafenib also undergoes cytochrome P450 (CYP)-dependent biotransformation to the N-oxide and other metabolites.	Sorafenib	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-45	
22513143-4	2012	In the present study CYP-mediated pathways of sorafenib oxidation in human liver were evaluated.	Sorafenib	46-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	21-24